We know there’s been a lot of recent news about Zantac. At Sanofi, patient safety and the quality of our products are our top priorities. Evaluations of the product are on-going. However, due to inconsistencies in preliminary test results of the active ingredient used in Zantac, Sanofi has, as a precautionary measure, made the decision to conduct a voluntary recall of Zantac in Canada and the U.S. as the investigation continues.
At Sanofi, we are committed to being transparent with patients and will continue to share updates as available.
For further information, contact 1-800-636-3664.